INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27501, 5201, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27502, 5208, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27503, 5209, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27504, 5210, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27505, 5211, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27506, 5293, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27507, 5646, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27508, 7078, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27509, 7079, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27510, 7081, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27511, 7082, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27512, 7086, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27513, 11287, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27514, 11289, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27515, 13902, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27516, 21568, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27517, 21569, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27518, 21572, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27519, 21574, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27520, 23151, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27521, 23153, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27522, 28052, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27523, 28053, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27524, 28054, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27525, 28056, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27526, 28057, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27527, 28058, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27528, 28060, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27529, 28061, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27530, 28436, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27531, 28774, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27532, 28775, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27533, 5201, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27534, 5208, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27535, 5209, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27536, 5210, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27537, 5211, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27538, 5293, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27539, 5646, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27540, 7078, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27541, 7079, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27542, 7081, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27543, 7082, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27544, 7086, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27545, 11287, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27546, 11289, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27547, 13902, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27548, 21568, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27549, 21569, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27550, 21572, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27551, 21574, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27552, 23151, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27553, 23153, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27554, 28052, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27555, 28053, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27556, 28054, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27557, 28056, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27558, 28057, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27559, 28058, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27560, 28060, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27561, 28061, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27562, 28436, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27563, 28774, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27564, 28775, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27565, 14611, 'Teriflunomide', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27566, 14611, 'Teriflunomide', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27567, 14611, 'Teriflunomide', 'Liver Diseases', 'Teriflunomide is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is necessary for patients with mild and moderate hepatic impairment.  Severe liver injury including fatal liver failure have been reported in patients treated with leflunomide.  A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.  Concomitant use of teriflunomide with other potentially hepatotoxic drugs may increase the risk of severe liver injury.  If drug-induced liver injury is suspected, discontinue therapy with teriflunomide and start an accelerated elimination procedure with cholestyramine or charcoal.  Patients with preexisting liver disease may be at increased risk of developing elevated serum transaminases while on therapy with teriflunomide.  It is recommended to obtain transaminase and bilirubin levels within 6 months before initiation of therapy.  Monitor ALT levels at least monthly for six months after starting therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27568, 14611, 'Teriflunomide', 'Hypertension', 'Teriflunomide may increase the blood pressure.  Caution should be taken when using this agent in hypertensive patients.  It is recommended to check blood pressure before the start of teriflunomide treatment and periodically thereafter and elevated blood pressure should be appropriately managed during treatment with teriflunomide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27569, 14611, 'Teriflunomide', 'IMMUNE SUPPRESSION', 'Cases of decrease in white blood cell count and in platelet count have been observed with the use teriflunomide.  Care should be taken when using this agent in immunosuppressed patients.  It is recommended to obtain a complete blood cell count within 6 months before the initiation of treatment and further monitoring should be based on signs and symptoms suggestive of bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27570, 14611, 'Teriflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy, including both polyneuropathy and mononeuropathy (e.g., carpal tunnel syndrome), has been reported with the use of teriflunomide.  Age older than 60 years, concomitant neurotoxic medications, and diabetes may increase the risk for peripheral neuropathy.  Care should be taken when prescribing this agent to patients at risk and if a patient develops symptoms consistent with peripheral neuropathy, such as bilateral numbness or tingling of hands or feet, consider discontinuing teriflunomide therapy and performing an accelerated elimination procedure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27571, 14611, 'Teriflunomide', 'Lung Diseases, Interstitial', 'Interstitial lung disease and worsening of preexisting interstitial lung disease, including acute interstitial pneumonitis, have been reported during treatment with teriflunomide.  Caution should be exercised when prescribing this agent to patients with pulmonary complication.  New onset or worsening pulmonary symptoms, such as cough and dyspnea, with or without associated fever, may be a reason for discontinuation of therapy and if discontinuation of the drug is necessary, consider initiation of an accelerated elimination procedure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27572, 14611, 'Teriflunomide', 'Tuberculosis', 'Cases of tuberculosis have been observed with the use of teriflunomide.  It is recommended to screen patients for latent tuberculosis infection before initiating therapy with teriflunomide.  The safety of teriflunomide in patients with a positive tuberculosis screen, and in individuals with latent tuberculosis infection is unknown.  Care should be exercised and in those patients testing positive, standard medical practice treatment should be given prior to teriflunomide therapy initiation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27573, 0, 'Tetraferric tricitrate decahydrate', 'Hemochromatosis', 'The use of ferric citrate is contraindicated in patients with iron overload syndromes (e.g., hemochromatosis).  Iron absorption from the use of ferric citrate may lead to excessive elevations in iron stores.  Patients receiving intravenous iron may require a reduction in dose or discontinuation of treatment.  It is recommended to assess iron parameters before therapy with ferric citrate and monitor iron parameters while on treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27574, 23204, 'Thalidomide', 'Seizures', 'Seizures, including grand mal convulsions, have been reported during post-approval use of thalidomide in clinical practice.  Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  Most patients had disorders that may have predisposed them to seizure activity, and it is not currently known whether thalidomide has any epileptogenic influence.  During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27575, 28097, 'Thalidomide', 'Seizures', 'Seizures, including grand mal convulsions, have been reported during post-approval use of thalidomide in clinical practice.  Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  Most patients had disorders that may have predisposed them to seizure activity, and it is not currently known whether thalidomide has any epileptogenic influence.  During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27576, 28098, 'Thalidomide', 'Seizures', 'Seizures, including grand mal convulsions, have been reported during post-approval use of thalidomide in clinical practice.  Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  Most patients had disorders that may have predisposed them to seizure activity, and it is not currently known whether thalidomide has any epileptogenic influence.  During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27577, 23204, 'Thalidomide', 'HIV Infections', 'In two separate studies involving HIV-seropositive patients, the use of thalidomide was associated with an increase in plasma viral RNA levels.  The clinical significance of this finding is unknown.  Both studies were published prior to the availability of highly active antiretroviral therapy, or HAART.  Until more information is available, the interim recommendation is to measure the viral load after the first and third months of thalidomide treatment and every 3 months thereafter (or as often as indicated by the patient''s antiretroviral regimen and clinical status).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27578, 28097, 'Thalidomide', 'HIV Infections', 'In two separate studies involving HIV-seropositive patients, the use of thalidomide was associated with an increase in plasma viral RNA levels.  The clinical significance of this finding is unknown.  Both studies were published prior to the availability of highly active antiretroviral therapy, or HAART.  Until more information is available, the interim recommendation is to measure the viral load after the first and third months of thalidomide treatment and every 3 months thereafter (or as often as indicated by the patient''s antiretroviral regimen and clinical status).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27579, 28098, 'Thalidomide', 'HIV Infections', 'In two separate studies involving HIV-seropositive patients, the use of thalidomide was associated with an increase in plasma viral RNA levels.  The clinical significance of this finding is unknown.  Both studies were published prior to the availability of highly active antiretroviral therapy, or HAART.  Until more information is available, the interim recommendation is to measure the viral load after the first and third months of thalidomide treatment and every 3 months thereafter (or as often as indicated by the patient''s antiretroviral regimen and clinical status).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27580, 23204, 'Thalidomide', 'Hypotension', 'The use of thalidomide has been associated with dizziness and orthostatic hypotension.  Therapy with thalidomide should be administered cautiously in patients with preexisting hypotension.  Rising slowly from a recumbent position is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27581, 28097, 'Thalidomide', 'Hypotension', 'The use of thalidomide has been associated with dizziness and orthostatic hypotension.  Therapy with thalidomide should be administered cautiously in patients with preexisting hypotension.  Rising slowly from a recumbent position is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27582, 28098, 'Thalidomide', 'Hypotension', 'The use of thalidomide has been associated with dizziness and orthostatic hypotension.  Therapy with thalidomide should be administered cautiously in patients with preexisting hypotension.  Rising slowly from a recumbent position is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27583, 23204, 'Thalidomide', 'Neutropenia', 'The use of thalidomide has been associated with decreased white blood cells counts, including neutropenia.  Therapy with thalidomide should be administered cautiously in patients with preexisting neutropenia.  Treatment should not be initiated if absolute neutrophil count is below 750/mm3.  Monitoring white blood cell count and differential routinely is recommended during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27584, 28097, 'Thalidomide', 'Neutropenia', 'The use of thalidomide has been associated with decreased white blood cells counts, including neutropenia.  Therapy with thalidomide should be administered cautiously in patients with preexisting neutropenia.  Treatment should not be initiated if absolute neutrophil count is below 750/mm3.  Monitoring white blood cell count and differential routinely is recommended during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27585, 28098, 'Thalidomide', 'Neutropenia', 'The use of thalidomide has been associated with decreased white blood cells counts, including neutropenia.  Therapy with thalidomide should be administered cautiously in patients with preexisting neutropenia.  Treatment should not be initiated if absolute neutrophil count is below 750/mm3.  Monitoring white blood cell count and differential routinely is recommended during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27586, 23204, 'Thalidomide', 'Peripheral Nervous System Diseases', 'The use of thalidomide has been associated with the development of peripheral neuropathy, which is sometimes irreversible.  Therapy with thalidomide should be administered cautiously in patients with preexisting neuropathy and only after the neuropathy has returned to baseline.  Patients should be monitored routinely for early signs of neuropathy including numbness, tingling, pain, or a burning sensation in the hands or feet.  If symptoms of drug-induced neuropathy develop, thalidomide should be discontinued immediately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27587, 28097, 'Thalidomide', 'Peripheral Nervous System Diseases', 'The use of thalidomide has been associated with the development of peripheral neuropathy, which is sometimes irreversible.  Therapy with thalidomide should be administered cautiously in patients with preexisting neuropathy and only after the neuropathy has returned to baseline.  Patients should be monitored routinely for early signs of neuropathy including numbness, tingling, pain, or a burning sensation in the hands or feet.  If symptoms of drug-induced neuropathy develop, thalidomide should be discontinued immediately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27588, 28098, 'Thalidomide', 'Peripheral Nervous System Diseases', 'The use of thalidomide has been associated with the development of peripheral neuropathy, which is sometimes irreversible.  Therapy with thalidomide should be administered cautiously in patients with preexisting neuropathy and only after the neuropathy has returned to baseline.  Patients should be monitored routinely for early signs of neuropathy including numbness, tingling, pain, or a burning sensation in the hands or feet.  If symptoms of drug-induced neuropathy develop, thalidomide should be discontinued immediately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27589, 11105, 'Tetracosactide', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of adrenocorticotropic agents may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if adrenocorticotropic therapy is administered to these patients.  During prolonged use, tuberculosis chemoprophylaxis may be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27590, 13507, 'Tetracosactide', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of adrenocorticotropic agents may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if adrenocorticotropic therapy is administered to these patients.  During prolonged use, tuberculosis chemoprophylaxis may be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27591, 11105, 'Tetracosactide', 'Adrenal Insufficiency', 'The use of adrenocorticotropic agents is contraindicated in patients with primary adrenocortical insufficiency because of the lack of adrenal responsiveness.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27592, 13507, 'Tetracosactide', 'Adrenal Insufficiency', 'The use of adrenocorticotropic agents is contraindicated in patients with primary adrenocortical insufficiency because of the lack of adrenal responsiveness.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27593, 11105, 'Tetracosactide', 'Water-Electrolyte Imbalance', 'Adrenocorticotropic agents may cause hypernatremia, hypokalemia, hypocalcemia, and fluid retention.  Therapy with these agents, particularly if intended for longer than brief periods, should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27594, 13507, 'Tetracosactide', 'Water-Electrolyte Imbalance', 'Adrenocorticotropic agents may cause hypernatremia, hypokalemia, hypocalcemia, and fluid retention.  Therapy with these agents, particularly if intended for longer than brief periods, should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27595, 11105, 'Tetracosactide', 'Peptic Ulcer Perforation', 'Adrenocorticotropic agents may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with adrenocorticotropic agents should be administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27596, 13507, 'Tetracosactide', 'Peptic Ulcer Perforation', 'Adrenocorticotropic agents may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with adrenocorticotropic agents should be administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27597, 11105, 'Tetracosactide', 'Adrenocortical Hyperfunction', 'The use of adrenocorticotropic agents is contraindicated in patients with adrenocortical hyperfunction.  These agents stimulate the release of cortisol and aldosterone and may aggravate symptoms of hyperadrenocorticism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27598, 13507, 'Tetracosactide', 'Adrenocortical Hyperfunction', 'The use of adrenocorticotropic agents is contraindicated in patients with adrenocortical hyperfunction.  These agents stimulate the release of cortisol and aldosterone and may aggravate symptoms of hyperadrenocorticism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27599, 11105, 'Tetracosactide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of adrenocorticotropic agents, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, adrenocorticotropic agents should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  For patients who have received prolonged adrenocorticotropic therapy who develop a severe or life-threatening infection, supplemental doses of rapid-acting corticosteroids may be required, since these patients may have hypothalamic-pituitary insufficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27600, 13507, 'Tetracosactide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of adrenocorticotropic agents, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, adrenocorticotropic agents should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  For patients who have received prolonged adrenocorticotropic therapy who develop a severe or life-threatening infection, supplemental doses of rapid-acting corticosteroids may be required, since these patients may have hypothalamic-pituitary insufficiency.', '3', '', 'DDInter', 0);
